Compounds > telocinobufagin
Page last updated: 2024-12-08

telocinobufagin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

telocinobufagin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID259991
CHEMBL ID463273
CHEBI ID80908
SCHEMBL ID866975
MeSH IDM0054035

Synonyms (36)

Synonym
nsc90782
nsc-90782
472-26-4
nsc-119989
nsc119989
bufa-20, 3,5,14-trihydroxy-, (3.beta.,5.beta.)-
telecinobufagin
5.beta.-bufa-20, 3.beta.,5,14-trihydroxy-
telocinobufagin
telocinobufogenin
5beta-bufa-20,22-dienolide, 3beta,5,14-trihydroxy-
brn 0056287
5-beta-bufa-20,22-dienolide, 3-beta,5,14-trihydroxy-
3-beta,5,14-trihydroxy-5-beta-bufa-20,22-dienolide
nsc 119989
3,5,14-trihydroxybufa-20,22-dienolide
bufa-20,22-dienolide, 3,5,14-trihydroxy-, (3beta,5beta)-
C17072
chebi:80908 ,
CHEMBL463273
5-[(3s,5s,8r,9s,10r,13r,14s,17r)-3,5,14-trihydroxy-10,13-dimethyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]pyran-2-one
telobufotoxin
4-18-00-02553 (beilstein handbook reference)
SCHEMBL866975
CS-3703
HY-N0885
AKOS030526152
NCGC00485919-01
Q27151407
3beta,5beta,14-trihydroxy-bufa-20,22-dienolide
telobufotoxin;telocinobufogenin
mfcd00468034
MS-26870
3beta,5,14-trihydroxy-5beta-bufa-20,22-dienolide
DTXSID701316861
bdbm50593518

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
steroid lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Signal transducer and activator of transcription 3Homo sapiens (human)Kd50.30000.50002.19934.5700AID1866245
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (76)

Processvia Protein(s)Taxonomy
positive regulation of vascular endothelial growth factor productionSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
temperature homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
eye photoreceptor cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of DNA-templated transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
protein import into nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
signal transductionSignal transducer and activator of transcription 3Homo sapiens (human)
transforming growth factor beta receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATSignal transducer and activator of transcription 3Homo sapiens (human)
nervous system developmentSignal transducer and activator of transcription 3Homo sapiens (human)
cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of autophagySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of gene expressionSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of gene expressionSignal transducer and activator of transcription 3Homo sapiens (human)
phosphorylationSignal transducer and activator of transcription 3Homo sapiens (human)
cytokine-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
sexual reproductionSignal transducer and activator of transcription 3Homo sapiens (human)
cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of cell migrationSignal transducer and activator of transcription 3Homo sapiens (human)
intracellular receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
response to estradiolSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-1 beta productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-10 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-6 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of interleukin-8 productionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of tumor necrosis factor productionSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to hormone stimulusSignal transducer and activator of transcription 3Homo sapiens (human)
leptin-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
somatic stem cell population maintenanceSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-15-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-2-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-9-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-11-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
regulation of multicellular organism growthSignal transducer and activator of transcription 3Homo sapiens (human)
glucose homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
eating behaviorSignal transducer and activator of transcription 3Homo sapiens (human)
mRNA transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to leptin stimulusSignal transducer and activator of transcription 3Homo sapiens (human)
response to leptinSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of erythrocyte differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of Notch signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of angiogenesisSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of glycolytic processSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of DNA-templated transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISignal transducer and activator of transcription 3Homo sapiens (human)
astrocyte differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activitySignal transducer and activator of transcription 3Homo sapiens (human)
regulation of cell cycleSignal transducer and activator of transcription 3Homo sapiens (human)
radial glial cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
retinal rod cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of feeding behaviorSignal transducer and activator of transcription 3Homo sapiens (human)
growth hormone receptor signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-6-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
T-helper 17 type immune responseSignal transducer and activator of transcription 3Homo sapiens (human)
T-helper 17 cell lineage commitmentSignal transducer and activator of transcription 3Homo sapiens (human)
energy homeostasisSignal transducer and activator of transcription 3Homo sapiens (human)
cellular response to interleukin-17Signal transducer and activator of transcription 3Homo sapiens (human)
cell surface receptor signaling pathway via STATSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of inflammatory response to woundingSignal transducer and activator of transcription 3Homo sapiens (human)
interleukin-10-mediated signaling pathwaySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of cytokine production involved in inflammatory responseSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of miRNA transcriptionSignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of metalloendopeptidase activitySignal transducer and activator of transcription 3Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of primary miRNA processingSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of stem cell differentiationSignal transducer and activator of transcription 3Homo sapiens (human)
negative regulation of neuron migrationSignal transducer and activator of transcription 3Homo sapiens (human)
regulation of cell population proliferationSignal transducer and activator of transcription 3Homo sapiens (human)
response to peptide hormoneSignal transducer and activator of transcription 3Homo sapiens (human)
defense responseSignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingSignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificSignal transducer and activator of transcription 3Homo sapiens (human)
DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor activitySignal transducer and activator of transcription 3Homo sapiens (human)
nuclear receptor activitySignal transducer and activator of transcription 3Homo sapiens (human)
signaling receptor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein kinase bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein phosphatase bindingSignal transducer and activator of transcription 3Homo sapiens (human)
chromatin DNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
signaling adaptor activitySignal transducer and activator of transcription 3Homo sapiens (human)
identical protein bindingSignal transducer and activator of transcription 3Homo sapiens (human)
protein homodimerization activitySignal transducer and activator of transcription 3Homo sapiens (human)
protein dimerization activitySignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
primary miRNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
lncRNA bindingSignal transducer and activator of transcription 3Homo sapiens (human)
DNA-binding transcription factor bindingSignal transducer and activator of transcription 3Homo sapiens (human)
RNA sequestering activitySignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
nucleusSignal transducer and activator of transcription 3Homo sapiens (human)
nucleoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
cytoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
cytosolSignal transducer and activator of transcription 3Homo sapiens (human)
plasma membraneSignal transducer and activator of transcription 3Homo sapiens (human)
RNA polymerase II transcription regulator complexSignal transducer and activator of transcription 3Homo sapiens (human)
chromatinSignal transducer and activator of transcription 3Homo sapiens (human)
transcription regulator complexSignal transducer and activator of transcription 3Homo sapiens (human)
cytoplasmSignal transducer and activator of transcription 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (92)

Assay IDTitleYearJournalArticle
AID1866271Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human PC-9 cells at 0.25 to 1 uM incubated for 5.5 to 7.5 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866282Inhibition of p-STAT3 Y705 levels in tumor of BALB/c nude mouse xenografted with human A549 cells at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866245Binding affinity to STAT3 (unknown origin) assessed as dissociation constant (KD) by surface plasmon resonance assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID773796Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay2013Journal of natural products, Oct-25, Volume: 76, Issue:10
C23 steroids from the venom of Bufo bufo gargarizans.
AID1866259Inhibition of STAT3 Y705 phosphorylation in human NCI-H1299 cells at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866249Inhibition of STAT3 signalling in human PC-9 cells assessed as reduction in BIRC5 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1765000Induction of apoptosis in human SK-MEL cells assessed as increase in cleaved PARP level at 0.1 to 0.5 uM incubated for 48 hrs by Western blot analysis
AID1866225Inhibition of cell migration of human A549 cells at 0.125 to 0.5 uM incubated for 24 hrs by Transwell migration assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866222Inhibition of cell proliferation of human A549 cells at 0.125 to 0.5 uM incubated for 24 hrs by EdU incorporation assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866216Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866226Inhibition of cell migration of human PC-9 cells at 0.125 to 0.5 uM incubated for 8 hrs by Transwell migration assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID357628Cytotoxicity against human KB cells after 72 hrs by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID1866219Inhibition of colony formation of human A549 cells assessed as reduction in colony number and size at 0.125 to 0.5 uM incubated for 24 hrs by colony formation assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866272Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human NCI-H1299 cells at 0.25 to 1 uM incubated for 5.5 to 7.5 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1764996Cytotoxicity against human SK-MEL cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
AID1866267Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human A549 cells at 0.25 to 1 uM by immunofluorescence microscopy2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1822696Time dependent inhibition of human CYP3A in human liver microsomes a 10 to 100 uM using midazolam as substrate preincubated for 30 mins in presence of NADPH-generating system followed by substrate addition incubated for 10 mins by LC-MS/MS analysis2022Journal of medicinal chemistry, 03-10, Volume: 65, Issue:5
Unique Oxidative Metabolism of Bufalin Generates Two Reactive Metabolites That Strongly Inactivate Human Cytochrome P450 3A.
AID1866246Inhibition of STAT3 signalling in human A549 cells assessed as reduction in MCL1 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866247Inhibition of STAT3 signalling in human A549 cells assessed as reduction in BIRC5 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866220Inhibition of colony formation of human PC-9 cells assessed as reduction in colony number and size at 0.125 to 0.5 uM incubated for 24 hrs by colony formation assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID155909Inhibitory activity against colchicine resistant parent primary liver carcinoma (PLC) cell line PLC/PRF/52002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID1866264Inhibition of STAT3 signalling in human PC-9 cells assessed as reduction in BIRC3 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866240Induction of apoptosis in human NCI-H1299 cells assessed as late apoptosis cells level at 0.25 uM incubated for 24 hrs by FITC annexin V/PI double-staining based flow cytometry (Rvb = 4.27%)2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID773793Cytotoxicity against KM mouse splenic lymphocytes assessed as cell viability at 5 uM2013Journal of natural products, Oct-25, Volume: 76, Issue:10
C23 steroids from the venom of Bufo bufo gargarizans.
AID1866228Inhibition of cell migration of human A549 cells at 0.125 to 0.5 uM incubated for 48 hrs by wound-healing migration assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866251Inhibition of STAT3 signalling in human NCI-H1299 cells assessed as reduction in MCL1 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866275Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human PC-9 cells at 0.25 to 1 uM pre-incubated for 10 hrs before IL6 stimulation for 0.5 mins by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID357629Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID1866237Induction of apoptosis in human PC-9 cells assessed as late apoptosis cells level at 1 uM incubated for 48 hrs by FITC annexin V/PI double-staining based flow cytometry (Rvb = 2.07%)2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866260Inhibition of STAT3 Y705 phosphorylation in human PC-9 cells at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866236Induction of apoptosis in human PC-9 cells assessed as reduction in Bcl2 levels at 0.25 to 1 uM incubated for 48 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866261Inhibition of STAT3 signalling in human NCI-H1299 cells assessed as reduction in MCL1 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866269Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human NCI-H1299 cells at 0.25 to 1 uM by immunofluorescence microscopy2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866218Cytotoxicity in human NCI-H1299 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866255Inhibition of STAT3 Y705 phosphorylation in human A549 cells at 1 uM incubated for 4 to 12 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866233Induction of apoptosis in human NCI-H1299 cells assessed as increase in cleaved PARP1 levels at 0.25 to 1 uM incubated for 24 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1765001Antiangiogenic activity in transgenic Tg(fli1:GFP) zebra fish embryo assessed as reduction in intersegmental blood vessels at 20 uM measured at 48 hrs postfertilization by fluorescence microscopy
AID1866279Toxicity in BALB/c nude mouse xenografted with human A549 cells assessed as toxic effect on liver at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days by H and E staining2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866265Inhibition of STAT3 signalling in human A549 cells assessed as reduction in MCL1 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866285Increase in cleaved PARP1 protein expression levels in tumor of BALB/c nude mouse xenografted with human A549 cells at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1765007Toxicity in zebra fish larvae assessed as pericardial edema at 100 uM measured at 48 hpf by stereomicroscopic analysis
AID1866266Inhibition of STAT3 signalling in human A549 cells assessed as reduction in BIRC3 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866232Induction of apoptosis in human PC-9 cells at 0.25 to 1 uM incubated for 48 hrs by FITC annexin V/PI double-staining based flow cytometry2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID357630Cytotoxicity against mouse MH60 cells after 72 hrs by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su.
AID1866221Inhibition of colony formation of human NCI-H1299 cells assessed as reduction in colony number and size at 0.125 to 0.5 uM incubated for 24 hrs by colony formation assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866231Induction of apoptosis in human NCI-H1299 cells at 0.25 to 1 uM incubated for 24 hrs by FITC annexin V/PI double-staining based flow cytometry2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866281Toxicity in BALB/c nude mouse xenografted with human A549 cells assessed as toxic effect on kidney at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days by H and E staining2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866223Inhibition of cell proliferation of human NCI-H1299 cells at 0.125 to 0.5 uM incubated for 24 hrs by EdU incorporation assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866262Inhibition of STAT3 signalling in human NCI-H1299 cells assessed as reduction in BIRC5 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866241Induction of apoptosis in human NCI-H1299 cells assessed as late apoptosis cells level at 0.5 uM incubated for 24 hrs by FITC annexin V/PI double-staining based flow cytometry (Rvb = 4.27%)2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866283Inhibition of MCL1 protein expression levels in tumor of BALB/c nude mouse xenografted with human A549 cells at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866252Inhibition of STAT3 mRNA expression in human NCI-H1299 cells at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866257Inhibition of STAT3 Y705 phosphorylation in human NCI-H1299 cells at 1 uM incubated for 4 to 12 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866224Inhibition of cell proliferation of human PC-9 cells at 0.125 to 0.5 uM incubated for 24 hrs by EdU incorporation assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866230Inhibition of cell migration of human PC-9 cells at 0.125 to 0.5 uM incubated for 48 hrs by wound-healing migration assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID155910Inhibitory activity against the primary liver carcinoma (PLC) cell line PLC/PRF/52002Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25
QSAR evaluation of the Ch'an Su and related bufadienolides against the colchicine-resistant primary liver carcinoma cell line PLC/PRF/5(1).
AID1765004Anti-melanoma activity against human SK-MEL cells xenografted in yolk of zebra fish at 10 uM measured after 48 hrs by CM-Dil staining based fluorescence microscopic analysis
AID1866277Toxicity in BALB/c nude mouse xenografted with human A549 cells assessed as induction of body weight loss at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866229Inhibition of cell migration of human NCI-H1299 cells at 0.125 to 0.5 uM incubated for 48 hrs by wound-healing migration assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866217Cytotoxicity in human PC-9 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866235Induction of apoptosis in human PC-9 cells assessed as increase in cleaved PARP1 levels at 0.25 to 1 uM incubated for 48 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866268Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human PC-9 cells at 0.25 to 1 uM by immunofluorescence microscopy2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866256Inhibition of STAT3 Y705 phosphorylation in human PC-9 cells at 1 uM incubated for 4 to 12 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866273Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human A549 cells at 0.25 to 1 uM pre-incubated for 10 hrs before IL6 stimulation for 0.5 mins by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866258Inhibition of STAT3 Y705 phosphorylation in human A549 cells at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866254Inhibition of STAT3 mRNA expression in human A549 cells at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1765002Antiangiogenic activity in transgenic Tg(fli1:GFP) zebra fish embryo assessed as reduction in angiogenic sprouts at 20 uM measured at 48 hrs postfertilization by fluorescence microscopy
AID1765008Toxicity in zebra fish larvae assessed as curved tail at 100 uM measured at 48 hpf by stereomicroscopic analysis
AID1765006Toxicity in zebra fish larvae assessed as death at 100 uM measured at 48 hpf by stereomicroscopic analysis
AID1866274Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human NCI-H1299 cells at 0.25 to 1 uM pre-incubated for 10 hrs before IL6 stimulation for 0.5 mins by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866244Binding affinity to STAT3 (unknown origin) assessed as dissociation rate constant (Kd) by surface plasmon resonance assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866270Inhibition of IL-6 induced p-STAT3 Y705 nuclear translocation in human A549 cells at 0.25 to 1 uM incubated for 5.5 to 7.5 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866242Induction of apoptosis in human NCI-H1299 cells assessed as late apoptosis cells level at 1 uM incubated for 24 hrs by FITC annexin V/PI double-staining based flow cytometry (Rvb = 4.27%)2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866238Induction of apoptosis in human PC-9 cells assessed as late apoptosis cells level at 0.25 uM incubated for 48 hrs by FITC annexin V/PI double-staining based flow cytometry (Rvb = 2.07%)2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866276Antitumor activity against human A549 cells xenografted in BALB/c nude mouse assessed as reduction in tumor size at 2 mg/kg, ip dosed every 2 days for total of 18 days2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866234Induction of apoptosis in human NCI-H1299 cells assessed as reduction in Bcl2 levels at 0.25 to 1 uM incubated for 24 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866253Inhibition of STAT3 mRNA expression in human PC-9 cells at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866227Inhibition of cell migration of human NCI-H1299 cells at 0.125 to 0.5 uM incubated for 8 hrs by Transwell migration assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866250Inhibition of STAT3 signalling in human NCI-H1299 cells assessed as reduction in BIRC5 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866263Inhibition of STAT3 signalling in human PC-9 cells assessed as reduction in MCL1 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866278Toxicity in BALB/c nude mouse xenografted with human A549 cells assessed as toxic effect on heart at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days by H and E staining2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866280Toxicity in BALB/c nude mouse xenografted with human A549 cells assessed as toxic effect on lung at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days by H and E staining2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID773795Cytotoxicity against human A549 cells after 24 hrs by MTT assay2013Journal of natural products, Oct-25, Volume: 76, Issue:10
C23 steroids from the venom of Bufo bufo gargarizans.
AID1866284Inhibition of BCL2 protein expression levels in tumor of BALB/c nude mouse xenografted with human A549 cells at 1 to 2 mg/kg, ip dosed every 2 days for total of 18 days by Western blot analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866248Inhibition of STAT3 signalling in human PC-9 cells assessed as reduction in MCL1 mRNA expression levels at 0.25 to 1 uM incubated for 6 to 8 hrs by qRT-PCR analysis2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866239Induction of apoptosis in human PC-9 cells assessed as late apoptosis cells level at 0.5 uM incubated for 48 hrs by FITC annexin V/PI double-staining based flow cytometry (Rvb = 2.07%)2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1866243Binding affinity to STAT3 (unknown origin) assessed as binding constant (Ka) by surface plasmon resonance assay2022Journal of natural products, 04-22, Volume: 85, Issue:4
Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (24)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (8.33)18.7374
1990's0 (0.00)18.2507
2000's5 (20.83)29.6817
2010's10 (41.67)24.3611
2020's7 (29.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.86

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.86 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.86)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (95.83%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
formaldehyde
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy		2.1110aldehyde;
one-carbon compound		allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
hydrogen
Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.		2.0210elemental hydrogen;
elemental molecule;
gas molecular entity		antioxidant;
electron donor;
food packaging gas;
fuel;
human metabolite
periplogenin
periplogenin: structure		2.0110
hellebrigenin
hellebrigenin: structure		2.0110
cinobufotalin
cinobufotalin: RN given refers to (3beta,5beta,15beta,16beta)-isomer; RN for cpd without isomeric designation not avail 4/90		8.0950
Gamabufogenin
gamabufotalin: antiangiogenic, main active compound isolated from Chinese medicine Chansu; structure in first source		2.4120steroid lactone
ouabain
Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.		2.793011alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone		anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite
digoxin
Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.		2.0610cardenolide glycoside;
steroid saponin		anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
ovalbumin
Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.		2.1110
digitoxigenin
Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin.. digitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22).		2.011014beta-hydroxy steroid;
3beta-hydroxy steroid
bufogenin
bufogenin: respiratory stimulant; from toad; structure. bufogenin : A steroid lactone of Chan su (toad venom), a Chinese medicine obtained from the skin venom gland of toads. A specific Na/K-ATPase protein inhibitor, it is used as a cardiotonic and central nervous system (CNS) respiratory agent, an analgesic and anesthetic, and as a remedy for ulcers.		2.9640epoxy steroid;
steroid lactone		EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
bufalin
bufalin: cardiotonic; powerful anesthetic & one of the active constituents of the Chinese drug ch'an su(senso); in Japan prepared from skin of Bufo bufo garfarizans; RN given refers to (3beta,5beta)-isomer. bufalin : A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo.		8.47014beta-hydroxy steroid;
3beta-hydroxy steroid		animal metabolite;
anti-inflammatory agent;
antineoplastic agent;
cardiotonic drug
desacetylcinobufagin
desacetylcinobufagin: structure in first source		2.4120
marinobufagenin
marinobufagenin: an endogenous digitalis-like factor; a Na(+),K(+)-ATPase inhibitor and cardiotonic agent; structure given in first source. marinobufagenin : A cardiotonic steroid secreted by the toad Bufo rubescens and other related species such as Bufo marinus. An endogenous Na/K-ATPase inhibitor, it is a vasoconstrictor with effects similar to digitalis.		3.1650epoxy steroid;
steroid hormone		EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope
cinobufagin
cinobufagin: isolated from Chinese medicinal preparation ch'an su; derived from toad venom		8.2660steroid lactone
bufotalin
bufotalin: from toads; structure		2.9640steroid lactone
arenobufagin
arenobufagin: structure given in first source		2.1310steroid lactone
bufadienolide
bufadienolide: isolated from liushen pills; RN given for (14beta)-isomer. bufadienolide : The simplest member of the class of bufadienolides that is bufanolide with unsaturation at positions 20 and 22.		2.1310bufadienolides
concanavalin a
Concanavalin A: A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Granulocytic Leukemia
[description not available]		0210
Cancer of Nasopharynx
[description not available]		0210
Leukemia, Myeloid
Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.		0210
Nasopharyngeal Neoplasms
Tumors or cancer of the NASOPHARYNX.		0210
Cancer of Liver
[description not available]		02.0110
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0110
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Carcinoma, Non-Small Cell Lung
[description not available]		03.3310
Cancer of Lung
[description not available]		03.3310
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		03.3310
Lung Neoplasms
Tumors or cancer of the LUNG.		03.3310
Bone Cancer
[description not available]		02.610
Osteogenic Sarcoma
[description not available]		02.610
Bone Neoplasms
Tumors or cancer located in bone tissue or specific BONES.		02.610
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		07.610
Breast Cancer
[description not available]		07.1710
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.1710
Cirrhosis
[description not available]		02.1710
Fibrosis
Any pathological condition where fibrous connective tissue invades any organ, usually as a consequence of inflammation or other injury.		07.1710
Kidney Diseases
Pathological processes of the KIDNEY or its component tissues.		02.1710
Salmonella Infections, Animal
Infections in animals with bacteria of the genus SALMONELLA.		02.1110
Benign Neoplasms
[description not available]		02.1310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.1310
Colorectal Cancer
[description not available]		02.1310
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.1310
Chronic Kidney Failure
[description not available]		02.0210
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		02.0210